121 related articles for article (PubMed ID: 24687907)
1. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.
Calais PJ; Turner JH
Ann Nucl Med; 2014 Jul; 28(6):531-9. PubMed ID: 24687907
[TBL] [Abstract][Full Text] [Related]
2. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol.
Olmstead C; Cruz K; Stodilka R; Zabel P; Wolfson R
Nucl Med Commun; 2015 Feb; 36(2):129-34. PubMed ID: 25356620
[TBL] [Abstract][Full Text] [Related]
3. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
4. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.
de Keizer B; van Aken MO; Feelders RA; de Herder WW; Kam BL; van Essen M; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):749-55. PubMed ID: 18210106
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
Teunissen JJ; Kwekkeboom DJ; Krenning EP
J Clin Oncol; 2004 Jul; 22(13):2724-9. PubMed ID: 15226340
[TBL] [Abstract][Full Text] [Related]
6. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
7. Effect of calculation method on kidney dosimetry in
Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
[TBL] [Abstract][Full Text] [Related]
8. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.
Villard L; Romer A; Marincek N; Brunner P; Koller MT; Schindler C; Ng QK; Mäcke HR; Müller-Brand J; Rochlitz C; Briel M; Walter MA
J Clin Oncol; 2012 Apr; 30(10):1100-6. PubMed ID: 22393097
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.
Claringbold PG; Brayshaw PA; Price RA; Turner JH
Eur J Nucl Med Mol Imaging; 2011 Feb; 38(2):302-11. PubMed ID: 21052661
[TBL] [Abstract][Full Text] [Related]
10. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.
Sandström M; Garske-Román U; Granberg D; Johansson S; Widström C; Eriksson B; Sundin A; Lundqvist H; Lubberink M
J Nucl Med; 2013 Jan; 54(1):33-41. PubMed ID: 23223392
[TBL] [Abstract][Full Text] [Related]
11. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
[TBL] [Abstract][Full Text] [Related]
13. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
Zandee WT; Brabander T; Blažević A; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; de Herder WW
J Clin Endocrinol Metab; 2019 Apr; 104(4):1336-1344. PubMed ID: 30566620
[TBL] [Abstract][Full Text] [Related]
14. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Kesavan M; Turner JH
Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
[TBL] [Abstract][Full Text] [Related]
15. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.
van Essen M; Krenning EP; Kooij PP; Bakker WH; Feelders RA; de Herder WW; Wolbers JG; Kwekkeboom DJ
J Nucl Med; 2006 Oct; 47(10):1599-606. PubMed ID: 17015894
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol.
Demir M; Abuqbeitah M; Uslu-Beşli L; Yıldırım Ö; Yeyin N; Çavdar İ; Vatankulu B; Gündüz H; Kabasakal L
J Radiol Prot; 2016 Jun; 36(2):269-78. PubMed ID: 27089552
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after
Spetz J; Rudqvist N; Langen B; Parris TZ; Dalmo J; Schüler E; Wängberg B; Nilsson O; Helou K; Forssell-Aronsson E
Nucl Med Biol; 2018 May; 60():11-18. PubMed ID: 29502008
[TBL] [Abstract][Full Text] [Related]
18. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
19. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
[TBL] [Abstract][Full Text] [Related]
20. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
